Advertisement

Uremic Toxins pp 165-169 | Cite as

Binding of Organic Acids to Surface Receptors of Lymphocytes as an Immunosuppressive Mechanism in Uremia

  • Tsutomu Sanaka
  • Yutaro Hayasaka
  • Yoichiro Kawashima
  • Takehide Takuma
  • Nobuhiro Sugino
  • Kazuo Ota
  • Paul F. Gulyassy
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 223)

Abstract

Some organic acids which inhibit binding of small ligands to plasma, so called protein binding inhibitors (PB-Ix), accumulate in body fluids of patients with renal failure. PB-Ix are believed to bind to sites on the surface of albumin and inhibit its detoxification, transport and reservoir functions1)2)3). They may play a wider toxic role, such as immunosuppression in uremic patients. PB-Ix have been shown to inhibit the mitogenic activity of lymphocytes4).

Keywords

Quinolinic Acid Mitogenic Activity Hippuric Acid Uremic Patient Normal Lymphocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    T. A. Depner and P. F. Gulyassy: Plasma protein binding in uremia--Excretion and characterization of an inhibitor. Kidney International 18:86–94, 1980.PubMedCrossRefGoogle Scholar
  2. 2).
    T. A. Depner, L. A. Stanfel, E. A. Jarrard and P. F. Gulyassy: Impaired plasma phenytoin binding in uremia--Effect of in vitro acidification and anion exchange resin. Nephron 25:231–237, 1980.PubMedCrossRefGoogle Scholar
  3. 3).
    T. Sanaka, H. Kasai, Y. Kawashima, F. Takahashi, Y. Hayasaka, K. Ota and N. Sugino: Chemical identification of protein binding inhibitor in uremic patients. Japanese Journal of Kidney and Dialysis 14:75–81, 1983.Google Scholar
  4. 4).
    T. Sanaka, Y. Kawashima, F. Takahashi, etal: Suppressive effect of uremic protein binding inhibitor on cultivated lymphocytes. Japanese J Nephrology 15:1063–1069, 1983.Google Scholar
  5. 5).
    T. Sanaka: Protein binding inhibitor in uremia. Japanese J Circulation 17:400–409, 1985.Google Scholar
  6. 6).
    K. Koide, J. Touyama, N. Inoue, et al: Oral Adsorbent. Japanese J Clinician (Nihon Rinsyou in Japanese) 43:422–440, 1985.Google Scholar
  7. 7).
    Y. Kawashima, T. Sanaka, N. Sugino: Suppressive effect of quinolinic acid on bone marrow erythroid growth in uremia. Abstract of Symposium Uremic Toxin, Gent, 1986.Google Scholar
  8. 8).
    T. Sanaka and K. Ota: Lymphocyte blastformation in uremic patients.Japanese J Clin Immunol 8:881–887, 1976.Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Tsutomu Sanaka
    • 1
  • Yutaro Hayasaka
    • 1
  • Yoichiro Kawashima
    • 1
  • Takehide Takuma
    • 1
  • Nobuhiro Sugino
    • 1
  • Kazuo Ota
    • 1
  • Paul F. Gulyassy
    • 1
  1. 1.Kidney CenterTokyo Women’s Medical CollegeTokyoJapan

Personalised recommendations